CASI 
Welcome,         Profile    Billing    Logout  
 9 Products   179 Diseases  9 Products   44 Trials   1691 News 
54 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Folotyn (pralatrexate) / Aurobindo
NCT06561048: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Recruiting
3
150
US
Soquelitinib, CPI-818, Belinostat, Beleodaq®, Pralatrexate, Folotyn®
Corvus Pharmaceuticals, Inc.
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
02/26
09/27
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting
2
50
US
Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar
University of Virginia, Celgene
PTCL
06/26
06/28
NCT03161223: Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Recruiting
1/2
148
US
Durvalumab, MEDI4736, Pralatrexate, Folotyn, Romidepsin, Depsipeptide, 5-Azacitidine, Vidaza, Oral 5-Azacitidine
University of Virginia
Lymphoma, T-Cell
02/23
02/23
NCT03598998: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Active, not recruiting
1/2
13
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pralatrexate, 10-propargyl-10-deazaaminopterin, Folotyn, PDX
City of Hope Medical Center, National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Subcutaneous Panniculitis-Like T-Cell Lymphoma
05/23
12/24
NCT03240211: Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Recruiting
1
37
US
Pembrolizumab, Keytruda, Pralatrexate, Folotyn, Decitabine, Dacogen
University of Virginia, Merck Sharp & Dohme LLC, Otsuka Pharmaceutical Development & Commercialization, Inc.
PTCL, CTCL
06/25
12/25
NCT06671717: Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

Not yet recruiting
N/A
25
RoW
Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
Peking University People's Hospital, Ruijin Hospital, Wuhan TongJi Hospital, West China Hospital
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
04/27
07/27
Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
FIL FLAZ12, NCT01827605 / 2012-000251-14: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Active, not recruiting
3
159
Europe
ZEVALIN, RIT, BEAM, ASCT
Fondazione Italiana Linfomi - ETS
Relapsed Follicular Lymphoma
10/19
01/24
NCT02320292: Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Completed
3
20
US
Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Yttrium Y-90 Ibritumomab Tiuxetan, IDEC-Y2B8, IDEC-Y2B8 monoclonal antibody, Y 90 Ibritumomab Tiuxetan, Y 90 Zevalin, Yttrium Y 90 Ibritumomab Tiuxetan, yttrium Y90 ibritumomab tiuxetan
Mayo Clinic, National Cancer Institute (NCI)
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma
02/21
11/23
2004-004349-16: Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high dose BEAM followed by autologous stem cell transplantation (ASCT)

Ongoing
2
75
Europe
Ibritumomab tiuxetan, Yttrium-90, CARMUSTINE, Mabthera, Aracytine, Alkeran, Etoposide, Ro45 2994, Kit for radiopharmaceutical preparation, Radiopharmaceutical precursor, Powder and solvent for solution for injection, Concentrate for solution for infusion, Powder and solvent for solution for infusion, Solution for infusion, Zevalin, Ytracis, BCNU, Mabthera100mg, Mabthera500mg, Aracytine, Alkeran, VP16
GELA Group
Low grade B-cell lymphoma CD20 positive:-Marginal zone-Lymphocytic-Follicular
 
 
2012-001768-31: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) ZENO-01 90Y IBRITUMOMAB TIUXETANO IN PAZIENTI CON LINFOMA A CELLULE B DELLA ZONA MARGINALE EXTRANODALE DEL TESSUTO LINFOIDE ASSOCIATO ALLA MUCOSA (LINFOMA MALT)

Ongoing
2
20
Europe
Powder and solvent for solution for infusion, ZEVALIN*INFUS 1F 2ML 1,6MG/ML
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, Spectrum pharmaceuticals, Irvine , California
MALT Lymphoma LINFOMA MALT, extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) LINFOMA A CELLULE B DELLA ZONA MARGINALE EXTRANODALE DEL TESSUTO LINFOIDE ASSOCIATO ALLA MUCOSA (LINFOMA MALT), Diseases [C] - Cancer [C04]
 
 
2006-006808-11: Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin\'s lymphoma.

Ongoing
2
50
Europe
ZEVALIN, ZEVALIN
AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
Patients with untreated follicular non-Hodgkin\'s lymphoma grade 1 or 2 according to REAL classification.
 
 
2006-004850-26: A phase II, open-label, prospective, multicenter study to evaluate theefficacy and safety of subsequent treatment with the Zevalin(ibritumomab tiuxetan) study in patients with follicular grade I-IIlymphoma after 4 cycles of Fludarabine-Mitoxantrone-Rituximab(FMR) therapy.

Ongoing
2
55
Europe
ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG, ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
follicular grade I-IIlymphoma
 
 
2006-004851-39: A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDYTO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENTTREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN)IN ELDERLY ( 60 YEARS) PATIENTS WITH DIFFUSE LARGE BCELLLYMPHOMA AFTER 4 CYCLES OF CHOP21 ﾖRITUXIMAB(CHOP21-R) THERAPY.

Ongoing
2
55
Europe
ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG, ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
DIFFUSE LARGE BCELLLYMPHOMA
 
 
2005-003796-20: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan (\"Zevalin\") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77)

Ongoing
2
12
Europe
Mabthera, Zevalin, Mabthera, Zevalin
HOVON Foundation
patients with diffuse Large B-Cell lymphoma, CD20-positive
 
 
2007-000699-18: Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI

Ongoing
2
222
Europe
PREDNISONE, RITUXIMAB, DOXORUBICINE, CYCLOPHOSPHAMIDE, VINDESINE, BLEOMYCIN, METHOTREXATE, G-CSF, VINCRISTINE, IFOSFAMIDE, ETOPOSIDE, CYTARABINE, CARMUSTINE, MELPHALAN, autologous stem cells, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN
Hospices Civils de Lyon, Groupe d\'Etude des Lymphomes de l\'Adulte(GELA)
CD20+ diffuse large B-cell lymphoma
 
 
2006-007083-28: Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.

Ongoing
2
60
Europe
prednisone, chlorambucil, etoposide, lomustine, 90Y-ibritumomab tiuxetan, A07EA03, Mabthera, Zevalin, Mabthera, Zevalin
HOVON foundation, KWF, Spectrum Pharmaceuticals
Aggressive B-cell NHL
 
 
2009-012944-17: Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (“Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.

Ongoing
2
31
Europe
90Y-ibritumomab tiuxetan, rituximab, prednisone, cyclophosphamide, vincristine, A07EA03, Zevalin, Mabthera, mabthera, Zevalin, Mabthera, mabthera
VUMC
follicular B cell NHL
 
 
NCT00577278: A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Checkmark P2 data - 1st line fNHL
Jun 2012 - Jun 2012: P2 data - 1st line fNHL
Completed
2
41
US
rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, allogeneic hematopoietic stem cell transplantation, indium In 111 ibritumomab tiuxetan, IDEC-In2B8, yttrium Y 90 ibritumomab tiuxetan, 90Y ibritumomab tiuxetan, IDEC Y2B8, Y90 Zevalin, Y90-labeled ibritumomab tiuxetan, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia, Lymphoma
05/19
12/23
NCT01359592: S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Completed
2
159
US
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, R-CHOP regimen, laboratory biomarker analysis, fludeoxyglucose F 18, selective external radiation therapy, yttrium Y 90 ibritumomab tiuxetan
SWOG Cancer Research Network, National Cancer Institute (NCI)
Lymphoma
06/20
12/23
NCT01811368: Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
20
US
rituximab, IDEC-C2B8, Mabthera, Rituxan, ibritumomab tiuxetan, Zevalin, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, total nodal irradiation, TLI, total lymphoid irradiation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell, allogeneic hematopoietic stem cell transplantation, cyclosporine, cyclosporin, cyclosporin A, CYSP, Sandimmune, mycophenolate mofetil, Cellcept, MMF
Joseph Tuscano, Spectrum Pharmaceuticals, Inc
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
04/23
12/23
Marqibo (vincristine liposomal) / Servier, Aurobindo
AREN0533, NCT00379340: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Active, not recruiting
3
395
Europe, Canada, US, RoW
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Conventional Surgery, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dactinomycin, Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1, Actinomycin IV, Actinomycin X 1, Actinomycin-[thr-val-pro-sar-meval], Cosmegen, DACT, Dactinomycine, Lyovac Cosmegen, Meractinomycin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Vincristine Sulfate Liposome, Marqibo
Children's Oncology Group, National Cancer Institute (NCI)
Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
06/16
 
OPTIMAL>60, NCT01478542 / 2010-019587-36: / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Checkmark P3 enrollment initiation in 1st line, adult NHL pts
Nov 2011 - Nov 2011: P3 enrollment initiation in 1st line, adult NHL pts
Completed
3
1152
Europe
Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab, optimised rituximab-schedule
Universität des Saarlandes, German High-Grade Non-Hodgkin's Lymphoma Study Group, Spectrum Pharmaceuticals, Inc
CD20+ Aggressive B-Cell Lymphoma
01/24
01/24
NCI-2018-01198, NCT03136146: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recruiting
2
42
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Clofarabine, Clofarex, Clolar, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate Liposome, Marqibo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
08/25
08/26
ChiCTR2200064650: A Phase I/II clinical study of rituximab in combination with cyclophosphamide, mitoxantrone liposome, vincristine and prednisone in newly treated massive diffuse large B-cell lymphoma (DLBCL) with big bulk

Not yet recruiting
1/2
45
 
The dose of mitoxantrone liposome is 16mg/m2 ;The dose of mitoxantrone liposome is 18mg/m2 ;The dose of mitoxantrone liposome is 20mg/m2 ;The dose of mitoxantrone liposome is 22mg/m2 ;Rituximab+Cyclophosphamide+Mitoxantrone liposome+Vincristine+Prednisone ;Rituximab+Cyclophosphamide+Mitoxantrone liposome+Vincristine+Prednisone
West China Hospital of Sichuan University; West China Hospital of Sichuan University, CSPC Ouyi Pharmaceutical Co., Ltd.
Diffuse large B-cell lymphoma
 
 
ECOG-ACRIN EA9152, NCT03504644: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Active, not recruiting
1/2
74
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Lumbar Puncture, LP, Spinal Tap, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto, Vincristine Liposomal, Lipid-Encapsulated Vincristine, Liposomal Vincristine, Onco TCS, Vincacine, VincaXome, Vincristine Liposome, Vincristine, Liposomal, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Recurrent T Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma
12/28
12/28
BRiM Study, NCT02257242: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Completed
1
11
US
Rituximab, Rituxan, anti-CD20 antibody, Bendamustine, Treanda, Vincristine sulfate liposome injection, Marqibo
Brown University, Spectrum Pharmaceuticals, Inc, Rhode Island Hospital, The Miriam Hospital
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone
08/20
11/20
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Recruiting
1
36
Canada, US, RoW
Marqibo
Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
08/21
12/22
NCT04933617: Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Terminated
1
8
US
Rituximab, Rituxan, Etoposide, Toposar, Etopophos, Copanlisib, Aliqopa, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Marqibo, Vincasar PFS, Prednisone, Deltasone, Rayos, Prednisone Intensol, ECHO, Echocardiogram, EKG, Electrocardiogram, MRI Brain, Magnetic resonance imaging of the brain, 18F-FDG - PET, Fludeoxyglucose F18, CT Scan, Computed tomography scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP), Spinal tap
National Cancer Institute (NCI)
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
11/23
11/23
LONCA, NCT05270057: Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressive B-cell Lymphoid Malignancies

Recruiting
1
33
US
Etoposide, Etopophos, Toposar, Vepesid, Doxorubicin, Lipodox, Lipodox 50, Doxil, Adriamycin, Rubex, Cyclophosphamide, Cytoxan, Neosar, Endoxan, Procytox, Revimmune, Rituximab, Rituxan, MabThera, Vincristine, Oncovin, Vincasar, Marqibo, Leurocristine, Prednisone, Deltasone, Orasone, Meticorten, Liquid Pred, Loncastuximab Tesirine 0.075 mg/kg by IV, Zynlonta, ADCT-402, loncastuximab tesirine-lpyl, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
Medical College of Wisconsin
B-cell Lymphoma, Burkitt Lymphoma
05/26
05/26
BI-1206 / BioInvent
2019-001923-11: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or AntiPDL1 Antibodies

Not yet recruiting
1/2
90
Europe
BI-1206, Concentrate for solution for infusion, Solution for injection, KEYTRUDA®
BioInvent International AB, BioInvent International AB, Merck & Co.
Advanced solid tumors who have relapsed or are refractory to anti-PD1 or anti-PDL1 therapy., Advanced solid tumors., Diseases [C] - Cancer [C04]
 
 
17-BI-1206-02, NCT03571568 / 2018-000444-26: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Recruiting
1/2
140
Europe, US, RoW
BI-1206, Rituximab, Ruxience, Acalabrutinib, Calquence
BioInvent International AB
Indolent B-Cell Non-Hodgkin Lymphoma
09/26
09/26
KEYNOTE-A04, NCT04219254 / 2019-001923-11: A Study of BI-1206 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Recruiting
1/2
197
Europe, US
BI1206, Pembrolizumab 25mg/mL (MK-3475)
BioInvent International AB, Merck Sharp & Dohme LLC
Solid Tumor, Adult
11/27
11/27
Yuanruida (inaticabtagene autoleucel) / CASI
2019-000910-12: A Double-blinded, Parallel-group, Randomized, Active-controlled Phase 2 Clinical Trial to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous HY-001 Versus Standard Colistin Methanesulfonate Sodium Monotherapy in Patients with Complicated Urinary Tract Infection (with or without pyelonephritis) or Acute Uncomplicated Pyelonephritis at Risk for Infection with Multidrug Resistant Gram-negative Pathogens.

Not yet recruiting
2
28
Europe
HY001, CMS, HY001, Powder and solution for solution for injection, Powder for solution for infusion, Colistin TZF
Helperby Therapeutics Ireland Limited, Helperby Therapeutics Ireland Limited
complicated urinary tract infection (cUTI)., A cUTI is an infection of the lower or upper urinary tract which can be caused by the presence of germs called bacteria., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
2
100
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Relapsed or Refractory Acute Lymphoblastic Leukemia
09/22
12/26
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
2
60
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Non-Hodgkin's Lymphoma
03/24
09/25
NCT06608732: Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

Recruiting
2
20
RoW
Inaticabtagene autoleucel
Institute of Hematology & Blood Diseases Hospital, China, Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
07/28
07/28
NCT06718244: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Recruiting
2
20
RoW
single dose of Inaticabtagene autoleucel, Inati-cel, CNCT-19
Ruijin Hospital
Acute Lymphoblastic Leukemia
12/29
12/29
JUVENTAS-ALL05, NCT06777264: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

Not yet recruiting
2
20
NA
Biological: single dose of Inaticabtagene autoleucel, Inati-cel, CNCT-19
First Affiliated Hospital of Zhejiang University
Acute Lymphoblastic Leukemia, B Cell ALL
12/26
01/27
NCT04690192: CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Active, not recruiting
1/2
20
RoW
CNCT19, Gemcitabine Injection, busulfan, Melphalan Injection
Zou Dehui, Juventas Cell Therapy Ltd.
Large B-cell Lymphoma
12/23
12/24
NCT05667506: A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

Recruiting
1/2
47
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
07/25
12/26
NCT04230473: A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed
1
10
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Relapsed or Refractory Acute Lymphoblastic Leukemia
12/20
11/22
HY-CD19 CART-002, NCT04232826: A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

Completed
1
9
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Diffuse Non-Hodgkin Lymphoma
01/21
11/22
NCT06316791: Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Recruiting
1
24
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Lupus Erythematosus, Systemic
12/25
12/25
NCT06231368: CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Recruiting
1
6
RoW
CNCT19 CAR-T cell therapy
Institute of Hematology & Blood Diseases Hospital, China, Juventas Cell Therapy Ltd.
Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T, Failure of Three or More Lines of Therapy
01/25
08/25
NCT05930314: CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

Enrolling by invitation
1
12
RoW
CNCT19 cell injection
Peking Union Medical College Hospital
Refractory Systemic Lupus Erythematosus, Lupus Nephritis, Immune Thrombocytopenia
05/24
05/25
NCT06676982: Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma

Not yet recruiting
1
12
RoW
anti-CD19 CAR-T
Zhejiang University, Juventas Cell Therapy Ltd.
Advanced Hepatocellular Carcinoma
07/26
08/26
NCT06826430: Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

Not yet recruiting
1
12
NA
Inaticabtagene autoleucel Injection
Juventas Cell Therapy Ltd.
Autoimmune Thrombocytopenia
03/26
12/27
NCT06461351: Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

Active, not recruiting
N/A
1000
RoW
Inaticabtagene autoleucel Injection, CNCT19
Juventas Cell Therapy Ltd.
B-cell Tumors
05/39
03/40
NCT06450067: Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

Recruiting
N/A
200
RoW
Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
06/26
06/29
ChiCTR2200062591: Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseases

Recruiting
N/A
27
 
anti CD19 cell therapy ;anti CD19 cell therapy ;anti-CD19 cell therapy
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Juventas Cell Therapy Ltd.
autoimmune diseases
 
 
CID-103 / CASI, Precision Autoimmune Therap
NCT04758767: CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

Completed
1
10
Europe
CID-103
CASI Pharmaceuticals, Inc.
Multiple Myeloma
01/23
01/23
CB-5339 / CASI
NCT04449562: A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1
40
US
CB-5339
National Cancer Institute (NCI)
Advanced Solid Tumors, Advanced Lymphomas
03/23
03/23
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed
1
55
US, RoW
CB-5339, CB-5339 Tosylate
Cleave Therapeutics, Inc.
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
07/23
07/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Folotyn (pralatrexate) / Aurobindo
NCT06561048: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Recruiting
3
150
US
Soquelitinib, CPI-818, Belinostat, Beleodaq®, Pralatrexate, Folotyn®
Corvus Pharmaceuticals, Inc.
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
02/26
09/27
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting
2
50
US
Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar
University of Virginia, Celgene
PTCL
06/26
06/28
NCT03161223: Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Recruiting
1/2
148
US
Durvalumab, MEDI4736, Pralatrexate, Folotyn, Romidepsin, Depsipeptide, 5-Azacitidine, Vidaza, Oral 5-Azacitidine
University of Virginia
Lymphoma, T-Cell
02/23
02/23
NCT03598998: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Active, not recruiting
1/2
13
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pralatrexate, 10-propargyl-10-deazaaminopterin, Folotyn, PDX
City of Hope Medical Center, National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Subcutaneous Panniculitis-Like T-Cell Lymphoma
05/23
12/24
NCT03240211: Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Recruiting
1
37
US
Pembrolizumab, Keytruda, Pralatrexate, Folotyn, Decitabine, Dacogen
University of Virginia, Merck Sharp & Dohme LLC, Otsuka Pharmaceutical Development & Commercialization, Inc.
PTCL, CTCL
06/25
12/25
NCT06671717: Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

Not yet recruiting
N/A
25
RoW
Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
Peking University People's Hospital, Ruijin Hospital, Wuhan TongJi Hospital, West China Hospital
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
04/27
07/27
Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
FIL FLAZ12, NCT01827605 / 2012-000251-14: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Active, not recruiting
3
159
Europe
ZEVALIN, RIT, BEAM, ASCT
Fondazione Italiana Linfomi - ETS
Relapsed Follicular Lymphoma
10/19
01/24
NCT02320292: Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Completed
3
20
US
Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Yttrium Y-90 Ibritumomab Tiuxetan, IDEC-Y2B8, IDEC-Y2B8 monoclonal antibody, Y 90 Ibritumomab Tiuxetan, Y 90 Zevalin, Yttrium Y 90 Ibritumomab Tiuxetan, yttrium Y90 ibritumomab tiuxetan
Mayo Clinic, National Cancer Institute (NCI)
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma
02/21
11/23
2004-004349-16: Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high dose BEAM followed by autologous stem cell transplantation (ASCT)

Ongoing
2
75
Europe
Ibritumomab tiuxetan, Yttrium-90, CARMUSTINE, Mabthera, Aracytine, Alkeran, Etoposide, Ro45 2994, Kit for radiopharmaceutical preparation, Radiopharmaceutical precursor, Powder and solvent for solution for injection, Concentrate for solution for infusion, Powder and solvent for solution for infusion, Solution for infusion, Zevalin, Ytracis, BCNU, Mabthera100mg, Mabthera500mg, Aracytine, Alkeran, VP16
GELA Group
Low grade B-cell lymphoma CD20 positive:-Marginal zone-Lymphocytic-Follicular
 
 
2012-001768-31: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) ZENO-01 90Y IBRITUMOMAB TIUXETANO IN PAZIENTI CON LINFOMA A CELLULE B DELLA ZONA MARGINALE EXTRANODALE DEL TESSUTO LINFOIDE ASSOCIATO ALLA MUCOSA (LINFOMA MALT)

Ongoing
2
20
Europe
Powder and solvent for solution for infusion, ZEVALIN*INFUS 1F 2ML 1,6MG/ML
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, Spectrum pharmaceuticals, Irvine , California
MALT Lymphoma LINFOMA MALT, extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) LINFOMA A CELLULE B DELLA ZONA MARGINALE EXTRANODALE DEL TESSUTO LINFOIDE ASSOCIATO ALLA MUCOSA (LINFOMA MALT), Diseases [C] - Cancer [C04]
 
 
2006-006808-11: Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin\'s lymphoma.

Ongoing
2
50
Europe
ZEVALIN, ZEVALIN
AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
Patients with untreated follicular non-Hodgkin\'s lymphoma grade 1 or 2 according to REAL classification.
 
 
2006-004850-26: A phase II, open-label, prospective, multicenter study to evaluate theefficacy and safety of subsequent treatment with the Zevalin(ibritumomab tiuxetan) study in patients with follicular grade I-IIlymphoma after 4 cycles of Fludarabine-Mitoxantrone-Rituximab(FMR) therapy.

Ongoing
2
55
Europe
ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG, ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
follicular grade I-IIlymphoma
 
 
2006-004851-39: A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDYTO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENTTREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN)IN ELDERLY ( 60 YEARS) PATIENTS WITH DIFFUSE LARGE BCELLLYMPHOMA AFTER 4 CYCLES OF CHOP21 ﾖRITUXIMAB(CHOP21-R) THERAPY.

Ongoing
2
55
Europe
ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG, ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
DIFFUSE LARGE BCELLLYMPHOMA
 
 
2005-003796-20: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan (\"Zevalin\") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77)

Ongoing
2
12
Europe
Mabthera, Zevalin, Mabthera, Zevalin
HOVON Foundation
patients with diffuse Large B-Cell lymphoma, CD20-positive
 
 
2007-000699-18: Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI

Ongoing
2
222
Europe
PREDNISONE, RITUXIMAB, DOXORUBICINE, CYCLOPHOSPHAMIDE, VINDESINE, BLEOMYCIN, METHOTREXATE, G-CSF, VINCRISTINE, IFOSFAMIDE, ETOPOSIDE, CYTARABINE, CARMUSTINE, MELPHALAN, autologous stem cells, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN
Hospices Civils de Lyon, Groupe d\'Etude des Lymphomes de l\'Adulte(GELA)
CD20+ diffuse large B-cell lymphoma
 
 
2006-007083-28: Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.

Ongoing
2
60
Europe
prednisone, chlorambucil, etoposide, lomustine, 90Y-ibritumomab tiuxetan, A07EA03, Mabthera, Zevalin, Mabthera, Zevalin
HOVON foundation, KWF, Spectrum Pharmaceuticals
Aggressive B-cell NHL
 
 
2009-012944-17: Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (“Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.

Ongoing
2
31
Europe
90Y-ibritumomab tiuxetan, rituximab, prednisone, cyclophosphamide, vincristine, A07EA03, Zevalin, Mabthera, mabthera, Zevalin, Mabthera, mabthera
VUMC
follicular B cell NHL
 
 
NCT00577278: A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Checkmark P2 data - 1st line fNHL
Jun 2012 - Jun 2012: P2 data - 1st line fNHL
Completed
2
41
US
rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, allogeneic hematopoietic stem cell transplantation, indium In 111 ibritumomab tiuxetan, IDEC-In2B8, yttrium Y 90 ibritumomab tiuxetan, 90Y ibritumomab tiuxetan, IDEC Y2B8, Y90 Zevalin, Y90-labeled ibritumomab tiuxetan, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia, Lymphoma
05/19
12/23
NCT01359592: S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Completed
2
159
US
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, R-CHOP regimen, laboratory biomarker analysis, fludeoxyglucose F 18, selective external radiation therapy, yttrium Y 90 ibritumomab tiuxetan
SWOG Cancer Research Network, National Cancer Institute (NCI)
Lymphoma
06/20
12/23
NCT01811368: Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
20
US
rituximab, IDEC-C2B8, Mabthera, Rituxan, ibritumomab tiuxetan, Zevalin, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, total nodal irradiation, TLI, total lymphoid irradiation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell, allogeneic hematopoietic stem cell transplantation, cyclosporine, cyclosporin, cyclosporin A, CYSP, Sandimmune, mycophenolate mofetil, Cellcept, MMF
Joseph Tuscano, Spectrum Pharmaceuticals, Inc
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
04/23
12/23
Marqibo (vincristine liposomal) / Servier, Aurobindo
AREN0533, NCT00379340: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Active, not recruiting
3
395
Europe, Canada, US, RoW
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Conventional Surgery, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dactinomycin, Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1, Actinomycin IV, Actinomycin X 1, Actinomycin-[thr-val-pro-sar-meval], Cosmegen, DACT, Dactinomycine, Lyovac Cosmegen, Meractinomycin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Vincristine Sulfate Liposome, Marqibo
Children's Oncology Group, National Cancer Institute (NCI)
Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
06/16
 
OPTIMAL>60, NCT01478542 / 2010-019587-36: / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Checkmark P3 enrollment initiation in 1st line, adult NHL pts
Nov 2011 - Nov 2011: P3 enrollment initiation in 1st line, adult NHL pts
Completed
3
1152
Europe
Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab, optimised rituximab-schedule
Universität des Saarlandes, German High-Grade Non-Hodgkin's Lymphoma Study Group, Spectrum Pharmaceuticals, Inc
CD20+ Aggressive B-Cell Lymphoma
01/24
01/24
NCI-2018-01198, NCT03136146: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recruiting
2
42
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Clofarabine, Clofarex, Clolar, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate Liposome, Marqibo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
08/25
08/26
ChiCTR2200064650: A Phase I/II clinical study of rituximab in combination with cyclophosphamide, mitoxantrone liposome, vincristine and prednisone in newly treated massive diffuse large B-cell lymphoma (DLBCL) with big bulk

Not yet recruiting
1/2
45
 
The dose of mitoxantrone liposome is 16mg/m2 ;The dose of mitoxantrone liposome is 18mg/m2 ;The dose of mitoxantrone liposome is 20mg/m2 ;The dose of mitoxantrone liposome is 22mg/m2 ;Rituximab+Cyclophosphamide+Mitoxantrone liposome+Vincristine+Prednisone ;Rituximab+Cyclophosphamide+Mitoxantrone liposome+Vincristine+Prednisone
West China Hospital of Sichuan University; West China Hospital of Sichuan University, CSPC Ouyi Pharmaceutical Co., Ltd.
Diffuse large B-cell lymphoma
 
 
ECOG-ACRIN EA9152, NCT03504644: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Active, not recruiting
1/2
74
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Lumbar Puncture, LP, Spinal Tap, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto, Vincristine Liposomal, Lipid-Encapsulated Vincristine, Liposomal Vincristine, Onco TCS, Vincacine, VincaXome, Vincristine Liposome, Vincristine, Liposomal, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Recurrent T Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma
12/28
12/28
BRiM Study, NCT02257242: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Completed
1
11
US
Rituximab, Rituxan, anti-CD20 antibody, Bendamustine, Treanda, Vincristine sulfate liposome injection, Marqibo
Brown University, Spectrum Pharmaceuticals, Inc, Rhode Island Hospital, The Miriam Hospital
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone
08/20
11/20
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Recruiting
1
36
Canada, US, RoW
Marqibo
Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
08/21
12/22
NCT04933617: Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Terminated
1
8
US
Rituximab, Rituxan, Etoposide, Toposar, Etopophos, Copanlisib, Aliqopa, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Marqibo, Vincasar PFS, Prednisone, Deltasone, Rayos, Prednisone Intensol, ECHO, Echocardiogram, EKG, Electrocardiogram, MRI Brain, Magnetic resonance imaging of the brain, 18F-FDG - PET, Fludeoxyglucose F18, CT Scan, Computed tomography scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP), Spinal tap
National Cancer Institute (NCI)
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
11/23
11/23
LONCA, NCT05270057: Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressive B-cell Lymphoid Malignancies

Recruiting
1
33
US
Etoposide, Etopophos, Toposar, Vepesid, Doxorubicin, Lipodox, Lipodox 50, Doxil, Adriamycin, Rubex, Cyclophosphamide, Cytoxan, Neosar, Endoxan, Procytox, Revimmune, Rituximab, Rituxan, MabThera, Vincristine, Oncovin, Vincasar, Marqibo, Leurocristine, Prednisone, Deltasone, Orasone, Meticorten, Liquid Pred, Loncastuximab Tesirine 0.075 mg/kg by IV, Zynlonta, ADCT-402, loncastuximab tesirine-lpyl, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
Medical College of Wisconsin
B-cell Lymphoma, Burkitt Lymphoma
05/26
05/26
BI-1206 / BioInvent
2019-001923-11: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or AntiPDL1 Antibodies

Not yet recruiting
1/2
90
Europe
BI-1206, Concentrate for solution for infusion, Solution for injection, KEYTRUDA®
BioInvent International AB, BioInvent International AB, Merck & Co.
Advanced solid tumors who have relapsed or are refractory to anti-PD1 or anti-PDL1 therapy., Advanced solid tumors., Diseases [C] - Cancer [C04]
 
 
17-BI-1206-02, NCT03571568 / 2018-000444-26: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Recruiting
1/2
140
Europe, US, RoW
BI-1206, Rituximab, Ruxience, Acalabrutinib, Calquence
BioInvent International AB
Indolent B-Cell Non-Hodgkin Lymphoma
09/26
09/26
KEYNOTE-A04, NCT04219254 / 2019-001923-11: A Study of BI-1206 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Recruiting
1/2
197
Europe, US
BI1206, Pembrolizumab 25mg/mL (MK-3475)
BioInvent International AB, Merck Sharp & Dohme LLC
Solid Tumor, Adult
11/27
11/27
Yuanruida (inaticabtagene autoleucel) / CASI
2019-000910-12: A Double-blinded, Parallel-group, Randomized, Active-controlled Phase 2 Clinical Trial to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous HY-001 Versus Standard Colistin Methanesulfonate Sodium Monotherapy in Patients with Complicated Urinary Tract Infection (with or without pyelonephritis) or Acute Uncomplicated Pyelonephritis at Risk for Infection with Multidrug Resistant Gram-negative Pathogens.

Not yet recruiting
2
28
Europe
HY001, CMS, HY001, Powder and solution for solution for injection, Powder for solution for infusion, Colistin TZF
Helperby Therapeutics Ireland Limited, Helperby Therapeutics Ireland Limited
complicated urinary tract infection (cUTI)., A cUTI is an infection of the lower or upper urinary tract which can be caused by the presence of germs called bacteria., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
2
100
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Relapsed or Refractory Acute Lymphoblastic Leukemia
09/22
12/26
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
2
60
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Non-Hodgkin's Lymphoma
03/24
09/25
NCT06608732: Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

Recruiting
2
20
RoW
Inaticabtagene autoleucel
Institute of Hematology & Blood Diseases Hospital, China, Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
07/28
07/28
NCT06718244: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Recruiting
2
20
RoW
single dose of Inaticabtagene autoleucel, Inati-cel, CNCT-19
Ruijin Hospital
Acute Lymphoblastic Leukemia
12/29
12/29
JUVENTAS-ALL05, NCT06777264: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

Not yet recruiting
2
20
NA
Biological: single dose of Inaticabtagene autoleucel, Inati-cel, CNCT-19
First Affiliated Hospital of Zhejiang University
Acute Lymphoblastic Leukemia, B Cell ALL
12/26
01/27
NCT04690192: CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Active, not recruiting
1/2
20
RoW
CNCT19, Gemcitabine Injection, busulfan, Melphalan Injection
Zou Dehui, Juventas Cell Therapy Ltd.
Large B-cell Lymphoma
12/23
12/24
NCT05667506: A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

Recruiting
1/2
47
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
07/25
12/26
NCT04230473: A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed
1
10
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Relapsed or Refractory Acute Lymphoblastic Leukemia
12/20
11/22
HY-CD19 CART-002, NCT04232826: A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

Completed
1
9
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Diffuse Non-Hodgkin Lymphoma
01/21
11/22
NCT06316791: Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Recruiting
1
24
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Lupus Erythematosus, Systemic
12/25
12/25
NCT06231368: CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Recruiting
1
6
RoW
CNCT19 CAR-T cell therapy
Institute of Hematology & Blood Diseases Hospital, China, Juventas Cell Therapy Ltd.
Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T, Failure of Three or More Lines of Therapy
01/25
08/25
NCT05930314: CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

Enrolling by invitation
1
12
RoW
CNCT19 cell injection
Peking Union Medical College Hospital
Refractory Systemic Lupus Erythematosus, Lupus Nephritis, Immune Thrombocytopenia
05/24
05/25
NCT06676982: Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma

Not yet recruiting
1
12
RoW
anti-CD19 CAR-T
Zhejiang University, Juventas Cell Therapy Ltd.
Advanced Hepatocellular Carcinoma
07/26
08/26
NCT06826430: Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

Not yet recruiting
1
12
NA
Inaticabtagene autoleucel Injection
Juventas Cell Therapy Ltd.
Autoimmune Thrombocytopenia
03/26
12/27
NCT06461351: Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

Active, not recruiting
N/A
1000
RoW
Inaticabtagene autoleucel Injection, CNCT19
Juventas Cell Therapy Ltd.
B-cell Tumors
05/39
03/40
NCT06450067: Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

Recruiting
N/A
200
RoW
Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
06/26
06/29
ChiCTR2200062591: Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseases

Recruiting
N/A
27
 
anti CD19 cell therapy ;anti CD19 cell therapy ;anti-CD19 cell therapy
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Juventas Cell Therapy Ltd.
autoimmune diseases
 
 
CID-103 / CASI, Precision Autoimmune Therap
NCT04758767: CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

Completed
1
10
Europe
CID-103
CASI Pharmaceuticals, Inc.
Multiple Myeloma
01/23
01/23
CB-5339 / CASI
NCT04449562: A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1
40
US
CB-5339
National Cancer Institute (NCI)
Advanced Solid Tumors, Advanced Lymphomas
03/23
03/23
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed
1
55
US, RoW
CB-5339, CB-5339 Tosylate
Cleave Therapeutics, Inc.
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
07/23
07/23

Download Options